Connor Tsuchida
Scientific Co-Founder Azalea Therapeutics
Connor Tsuchida is a Scientific Co-Founder at Azalea Therapeutics, a biotechnology company pioneering in vivo genome editing therapies with cell and genomic precision. He earned his PhD in Bioengineering from UC Berkeley and UCSF, where he trained under Nobel Laureate Jennifer Doudna. His doctoral research focused on developing novel technologies to enhance the safety of CRISPR-Cas genome editing – work that was foundational to the founding of Azalea Therapeutics.
Seminars
Saturday 29th August 2026
In Vivo Generation Of TRAC-CAR-T Cells By Leveraging Enveloped Delivery Vehicles
1:30 pm
- T cell-specific delivery and genomic site-specific genome editing enables potent and safe in vivo CAR-T cell generation
- Precise genomic integration of the CAR behind the endogenous TRAC promoter enables homogenous CAR-T cell generation with enhanced potency from native regulation
- In vivo CAR-T cell efficacy and tolerability across numerous clinically relevant models support progression toward first in human readiness
